Skip to content
The Policy VaultThe Policy Vault

Rydapt (midostaurin) — CareFirst (Caremark)

Myeloid and/or lymphoid neoplasms with eosinophilia and FGFR1 or FLT3 rearrangement (chronic phase or blast phase)

Initial criteria

  • Diagnosis of myeloid and/or lymphoid neoplasms with eosinophilia with FGFR1 or FLT3 rearrangement in chronic phase or blast phase

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months